2021 annual results – Atos

Revenue at € 10,839 million, -2.5% at constant currency; -4.3% organically Operating margin at € 383 million, or 3.5% of revenue Free cash flow at €-419 million Net income Group share at €-2,962 million; normalized diluted EPS at €-1.97 … 2022: a pivotal year Revenue growth to bottom out: -0.5% […]

Destiny Pharma PLC unveils further positive results for c-difficile treatment as market research points to its commercial potential

NTCD-M3, which researchers are readying to phase III scientific trials, was the subject matter to a separate preclinical analyze by the US Office of Veterans Affairs Future Pharma PLC (Intention:DEST) hailed the ‘significant professional opportunity’ of its c-difficile treatment as it unveiled positive outcomes of a study carried out by […]

LPL Financial Announces Third Quarter 2021 Results

Key Financial Results Net Income was $103 million, translating to diluted earnings per share (“EPS”) of $1.26. EPS prior to amortization of intangible assets and acquisition costs* increased 23% year-over-year to $1.77. Gross profit* increased 25% year-over-year to $631 million. Core G&A* increased 19% year-over-year to $271 million. EBITDA* increased […]

LPL Financial Announces Second Quarter 2021 Results

Key Financial Results Diluted earnings per share (“EPS”) increased 15% year-over-year to $1.46. Net Income increased 17% year-over-year to $119 million. EPS Prior to Amortization of Intangible Assets and Acquisition Costs* increased 30% year-over-year to $1.85. Gross Profit* increased 23% year-over-year to $602 million. Core G&A* increased 13% year-over-year to […]

2020 annual results – Atos

Record high bookings All 2020 objectives achieved Order entry at € 13,330 million, +10% year-on-year at constant currency Book to bill ratio at 119% (excl. € 3 billion Siemens renewal) with Q4 at 130% Revenue at € 11,181 million, -3.0% organically thanks to a resilient business model Progressive recovery from […]

First half 2020 results – Atos

Strong commercial dynamic  Order entry up +9.4% year-on-year, Book to bill ratio at 112% (Q2 at 121%) Revenue at € 5,627 million, -2.8% organically (Q2 at -4.8%) Cost actions leading to an Operating margin at € 450 million, 8.0% of revenue Working capital timing effects leading to a Free cash […]